MBVax Bioscience

MBVax Bioscience is a Canadian biotechnology company focused on the development and revitalization of Coley's Toxins, a historical immunotherapy for cancer. The company's lead product, Mixed Bacterial Vaccine (MBV), consists of inactivated Streptococcus pyogenes and Serratia marcescens designed to stimulate a robust systemic immune response. MBVax aims to treat various refractory cancers, including melanoma, sarcoma, and lymphoma, by inducing a fever response that activates innate and adaptive immunity. The company has focused on producing MBV to modern GMP standards for use in clinical trials and compassionate use cases. Their approach represents one of the earliest forms of cancer immunotherapy, updated with contemporary manufacturing and regulatory rigor.